<DOC>
	<DOCNO>NCT00047021</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine cytarabine mitoxantrone treat patient recurrent refractory leukemia lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent Refractory Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine non-hematologic toxic effect high-dose cytarabine high-dose mitoxantrone patient recurrent refractory leukemia lymphoma . - Determine vitro T/NK lymphocyte proliferative response patient 's leukemia/lymphoma cell treatment regimen . OUTLINE : Patients receive high-dose cytarabine IV 1 hour day 1-5 high-dose mitoxantrone IV 15-30 minute day 5 . Patients also receive sargramostim ( GM-CSF ) subcutaneously begin day 14 continue blood count recover . Patients achieve least stable disease response may receive second course begin least 14 day first course complete . Patients follow 3 month . PROJECTED ACCRUAL : A total 20-30 patient accrue study within approximately 2-3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow must present : Histologically confirm acute myeloid leukemia acute lymphoblastic leukemia More 5 % blast bone marrow peripheral blood unrelated recovery normal hematopoiesis prior chemotherapy Failed least 1 attempt induction chemotherapy Diagnosis nonHodgkin 's lymphoma Hodgkin 's lymphoma Refractory relapse least 1 regimen standard chemotherapy Diagnosis chronic myelogenous leukemia accelerate phase blast crisis Received least 1 myelotoxic chemotherapy regimen Active CNS involvement allow PATIENT CHARACTERISTICS : Age 55 Performance status ECOG 02 Life expectancy At least 5 week Hematopoietic Lymphoma patient : WBC least 2,000/mm^3* Platelet count least 20,000/mm^3* NOTE : *Unless due bone marrow involvement disease process Hepatic Bilirubin great 3 time normal* AST/ALT great 3 time normal* Alkaline phosphatase great 3 time normal* No severe liver failure NOTE : *Unless related leukemia Renal Creatinine clearance great 50 mL/min No severe renal failure Cardiovascular LVEF least 45 % MUGA Pulmonary DLCO least 60 % predict Other HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychiatric illness would preclude informed consent No medical illness condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics At least 24 hour since prior hydroxyurea At least 1 week since prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>